Status:

UNKNOWN

The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19

Lead Sponsor:

First Affiliated Hospital of Wenzhou Medical University

Collaborating Sponsors:

Second Affiliated Hospital of Wenzhou Medical University

Wenzhou Central Hospital

Conditions:

COVID-19 Thalidomide

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of lung injury caused by COVID-19 can be an alternative target for current treatment. Patients w...

Detailed Description

Thalidomide has been clinically reported, and combined with antiviral drugs and other conventional treatments have achieved good results in the treatment of severe H1N1, especially after the death of ...

Eligibility Criteria

Inclusion

  • Age ≥18 years;
  • The laboratory (RT-PCR) confirmed the diagnosis of severe patients infected with CoVID-19 (refer to the fifth edition of the Chinese diagnosis and treatment guideline for trial); the diagnosis of new coronavirus pneumonia was confirmed, and any of the following: 1) Respiratory distress, breathing ≥30 beats / min; 2) In the resting state, the oxygen saturation is ≤93%; 3) Arterial blood oxygen partial pressure / oxygen concentration ≤300mmHg
  • The diagnosis is less than or equal to 12 days;

Exclusion

  • Severe liver disease (such as Child Pugh score ≥ C, AST\> 5 times the upper limit); severe renal dysfunction (the glomerulus is 30ml / min / 1.73m2 or less)
  • Pregnancy or breastfeeding or positive pregnancy test;
  • In the 30 days before the screening assessment, have taken any experimental treatment drugs for CoVID-19 (including off-label, informed consent use or trial-related);
  • Those with a history of thromboembolism, except for those caused by PICC.

Key Trial Info

Start Date :

February 18 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 30 2020

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT04273581

Start Date

February 18 2020

End Date

May 30 2020

Last Update

February 21 2020

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.